Jointly sponsored by ACCP and the American Society of Health-System Pharmacists

• Session Overview
• Program Content
• Faculty
• Target Audience and Program Goals
• CPE Credit
• BCOP Specialty Recertification Credit
• Technical Requirements
• Fees

The BCOP Clinical Sessions are one component of the professional development program developed by ACCP and the American Society of Health-System Pharmacists (ASHP) and approved for the recertification by the Board of Pharmacy Specialties (BPS) for the recertification of Board Certified Oncology Pharmacists (BCOPs). Successful completion of a web-based posttest will be required to earn recertification credit for the clinical sessions, live or home study.

The 2016 BCOP Clinical Sessions are offered in two parts. The first part is focused on Lung Cancer Therapy and Molecular Targets and will provide an overview of advances in lung cancer therapy as well as a detailed examination of the translations of molecular targets. The second part of the BCOP Clinical Sessions will examine the evolving treatment strategies in Multiple Myeloma, as well chemotherapy induced nausea and vomiting in the pediatric patient.

	Jill Bates, Pharm.D., MS, BCOP Assistant Professor of Clinical Education Clinical Pharmacy Specialist in Malignant Hematology University of North Carolina Chapel Hill, North Carolina
	Gary W. Jean, Pharm.D., BCOP Assistant Professor Texas Tech University Health Sciences Center School of Pharmacy Clinical Coordinator Clements University Hospital Dallas, Texas
	Jennifer L. Thackray, Pharm.D., BCPS, BCPPS Pediatric Oncology Clinical Pharmacy Specialist Memorial Sloan Kettering Cancer Center New York, New York
	Christine M. Walko, Pharm.D., BCOP Clinical Pharmacogenetics Scientist Moffitt Cancer Center Tampa, Florida

Clinical Pharmacists and BCOPs providing care to patients with cancer.

At the conclusion of the program, the participant should be able to:

Lung Cancer Therapy and Molecular Targets

1. Review the common mutations present in NSCLC.
2. Review the history of targeted therapy in advanced NSCLC.
3. Discuss the common targeted treatment modalities in advanced NSCLC.
4. Identify the current barriers to targeted therapy in the management of advanced NSCLC.
5. Explain the purpose of a molecular tumor board and demonstrate the value they add to treatment recommendations.
6. Outline the support and process for obtaining off label genetic-guided therapy when clinical trials are not available.
7. Discuss less common genetic alterations in NSCLC and their associated treatmets and outcomes.
8. Identify future challenges to the implementation of genetic-guided therapy into standard oncology clinical practice.

Multiple Myeloma and Pediatric CINV II

1. Examine prognostic implications and outline patient-specific treatment for multiple myeloma.
2. Discuss pertinent literature related to daratumumab, elotuzumab and ixazomib.
3. Illustrate current role in therapy of novel agents to treat multiple myeloma.
4. Define the phases of chemotherapy-induced nausea and vomiting (CINV) and recognize the risk factors for CINV in a pediatric patient.
5. Analyze the safety and efficacy of aprepitant and palonosetron in pediatric patients.
6. Develop a plan for prevention and treatment of each phase of CINV.
7. Modify an antiemetic regimen for a pediatric patient with breakthrough CINV.

The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Both BCOP Clinical Sessions are application-based activities.

BCOP Clinical Sessions – Lung Cancer Therapy and Molecular Targets;
Activity Number: 0217-9999-16-135-H01-P; 2.0 contact hours.

BCOP Clinical Sessions – Multiple Myeloma and Pediatric CINV II;
Activity Number: 0217-9999-16-145-H01-P; 2.0 contact hours.

To earn continuing pharmacy education (CPE) credit and to receive your continuing pharmacy education statement of credit for this activity, participants must successfully complete a Web-based posttest by October 1, 2019. Partial credit is not available for each activity.

To be eligible for 4.0 CPE hours of recertification credit, BCOPs must listen to all 4.0 contact hours of the recorded presentations and then successfully complete a Web-based posttest by March 31, 2017. Partial credit is available for this activity.

ACCP, as the official provider approved by BPS, will record and report recertification credit earned for this activity directly to BPS.

Requires an Internet browser and Adobe Reader.

ASHP members, please call (913) 492-3311 to receive the member discount.

Description	Price	Nonmember	Cart
Specialty Recertification Program with 4.0 Continuing Education Credits Includes audio/slide synchronized presentations, handouts, and online CPE test. The ACPE Universal Activity Number is listed under Continuing Pharmacy Education Credit above. Test submission deadline for recertification is March 31, 2017.	$150.00	$210.00
Online Program with 4.0 Continuing Education Credits (CPE only) Includes audio/slide synchronized presentations, handouts, and online CPE test. The ACPE Universal Activity Number is listed under Continuing Pharmacy Education Credit above. This product does not include specialty recertification credit. Test submission deadline for CPE credit is October 1, 2019.	$100.00	$160.00

No financial support from external supporters was obtained for this course.